Bionano Genomics, Inc. (BNGO)
NASDAQ: BNGO · Real-Time Price · USD
1.150
+0.050 (4.55%)
At close: Nov 6, 2026, 4:00 PM EST
1.148
-0.002 (-0.16%)
After-hours: Nov 6, 2026, 7:30 PM EST
Bionano Genomics Revenue
Bionano Genomics had revenue of $15.33M in the twelve months ending June 30, 2026, down -44.09% year-over-year. In the year 2025, Bionano Genomics had annual revenue of $28.51M, down -7.37%. That makes Bionano Genomics the 31,320th largest company in the world by revenue and 4,137th in the United States.
Revenue (ttm)
$15.33M
Revenue Growth
-44.09%
P/S Ratio
0.45
Revenue / Employee
$311,093
Employees
97
Market Cap
13.54M
Revenue by Geography
- Europe, The Middle East and Africa (EMEA) 14.11M 49.5%
- Americas (excl. United States) 7.67M 26.9%
- United States 4.51M 15.8%
- Asia Pacific 2.22M 7.8%
Fiscal year ended Dec 31, 2025 See the full Bionano Genomics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 28.51M | -2.27M | -7.37% |
| Dec 31, 2024 | 30.78M | -5.34M | -14.79% |
| Dec 31, 2023 | 36.12M | 8.31M | 29.90% |
| Dec 31, 2022 | 27.80M | 9.82M | 54.62% |
| Dec 31, 2021 | 17.98M | 9.48M | 111.47% |
| Dec 31, 2020 | 8.50M | -1.63M | -16.06% |
| Dec 31, 2019 | 10.13M | -1.87M | -15.59% |
| Dec 31, 2018 | 12.00M | 2.50M | 26.26% |
| Dec 31, 2017 | 9.51M | 2.71M | 39.93% |
| Dec 31, 2016 | 6.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harvard Bioscience | 87.81M |
| Retractable Technologies | 33.90M |
| Precision Optics Corporation | 31.53M |
| Nephros | 20.72M |
| Milestone Scientific | 9.42M |
| Lucyd | 3.41M |
| Femasys | 2.30M |
| Cuprina Holdings (Cayman) Limited | 38.79K |
BNGO News
- 5 days ago - Bionano Genomics Registration statement: Registration filing - Filings
- 10 days ago - Bionano Genomics files to sell 1.33M shares of common stock - TheFly
- 10 days ago - Bionano to Report Third Quarter 2026 Financial Results and Host a Conference Call Webcast on November 10, 2026 - GlobeNewsWire
- 11 days ago - Bionano Genomics Registration statement: Registration filing - Filings
- 6 weeks ago - Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies - GlobeNewsWire
- 7 weeks ago - Bionano Genomics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 7 weeks ago - Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia - GlobeNewsWire
- 1 month ago - Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms - GlobeNewsWire